https://www.selleckchem.com/pr....oducts/forskolin.htm
Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T have been approved for advanced prostate cancer. Appropriate drug selection remains crucial in this evolving landscape to derive maximum benefit for the patients. We summarize clinical trials leading to recent drug appro
Aimer
Commentaire
Partagez
